TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04382248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone App
Description: An app for monitoring medications, blood pressure, exercise, healthy eating

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: An app for monitoring medications, blood pressure, exercise, healthy eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: in-person coaching
Study: NCT03571919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Intravenous bolus of saline and then infusion
Study: NCT04518007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study: NCT04431791

Intervention type: DRUG
Intervention: Regorafenib
Description: oral regorafenib

Intervention type: DRUG
Intervention: Fruquintinib
Description: oral fruquintinib
Study: NCT01930292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Debio 1143
Description: Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Debio 1143
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Debio 1143
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Debio 1143
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
Study: NCT00563238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
Study: NCT00249470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence & Work
Description: Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Work Only
Description: Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
Study: NCT00684606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin IV
Description: 5 miu/1000ml Glu/Saline
Study: NCT04116645

Intervention type: OTHER
Intervention: genital and rectal swab
Description: 6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.

Intervention type: OTHER
Intervention: genital and rectal swab
Description: 6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
Study: NCT00684853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.25 mg of bevacizumab intravitreal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vetaporfin
Description: full fluence of vetaporfin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vetaporfin
Description: full fluence of vetaporfin
Study: NCT01637350

Intervention type: PROCEDURE
Intervention: digestive tract reconstruction
Description: Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction

Intervention type: PROCEDURE
Intervention: digestive tract reconstruction
Description: Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction

Intervention type: PROCEDURE
Intervention: digestive tract reconstruction
Description: Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction

Intervention type: PROCEDURE
Intervention: digestive tract reconstruction
Description: Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Study: NCT02152410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
Study: NCT03880851

Intervention type: RADIATION
Group type: OTHER
Intervention: Plan adaptation of Radiation Treatment in case of anatomical changes
Description: Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
Study: NCT04853225

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study
Study: NCT00573027

Intervention type: PROCEDURE
Group type: OTHER
Intervention: noninvasive tests
Description: clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
Study: NCT02299531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size
Study: NCT04623333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT02180516

Intervention type: DRUG
Intervention: Meloxicam

Intervention type: DRUG
Intervention: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
Study: NCT02696369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine HCl with epinephrine 1:200,000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine HCl with epinephrine 1:80,000
Study: NCT00660348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: This is morphine given in the traditional methods.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic intrathecal pump
Description: This pump will be inserted into the research subject and then the pump will deliver morphine.
Study: NCT03904706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits only
Description: Formalized audit teams with monthly meetings at each facility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits with community feedback
Description: This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
Study: NCT03811795

Intervention type: OTHER
Group type: OTHER
Intervention: ECG monitoring with a Kardia Mobile monitor
Description: The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.

Intervention type: OTHER
Group type: OTHER
Intervention: ECG monitoring with a Kardia Mobile monitor
Description: The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
Study: NCT02311491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic coated orthodontic archwire
Description: Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
Study: NCT02581774

Intervention type: OTHER
Intervention: normal delivery tracking
Description: normal delivery tracking

Intervention type: OTHER
Intervention: normal delivery tracking
Description: normal delivery tracking
Study: NCT03131856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention programme
Description: The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
Study: NCT03726177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 162 mg
Description: Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 81 mg
Description: Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT04656067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin ,Tranexamic acid and Ethamsylate
Description: Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin ,Tranexamic acid and Ethamsylate
Description: Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
Study: NCT02444091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
Study: NCT02869490

Intervention type: OTHER
Intervention: Data collection
Study: NCT03551210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Solution for infusion, 500 mg (250 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Capsules, 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: Solution for infusion, 500 mg (100 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (250 ml)
Description: 0.9% NaCl (250 ml), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (100 ml)
Description: 0.9% NaCl (100 ml), solution for infusion
Study: NCT00366990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Sodium Diet
Description: Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular Sodium Intake
Description: Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
Study: NCT01239368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)
Description: Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Th1/Tc1 Rapa Cell Therapy
Description: Th1/Tc1Rapa: 5 x 10e(6) cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Th1/Tc1 Rapa Cell Therapy
Description: Th1/Tc1Rapa: 5 x 10e(6) cells/kg
Study: NCT01182493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump (Medtronic Minimed Paradigm® VEO)
Description: The pump delivers insulin as specified by the patient
Study: NCT03012100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha Peptide Vaccine
Description: Given ID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sargramostim
Description: Given ID
Study: NCT02519920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.01ml/kg
Description: fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.02ml/kg
Description: fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.05ml/kg
Description: fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorescein sodium 0.1ml/kg
Description: fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
Study: NCT03926351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
Study: NCT03443804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test(DW1401)
Description: DW1401+Placebo of Stillen tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference(Stillen tab.)
Description: Stillen tab.+Placebo of DW1401
Study: NCT02091765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy.
Study: NCT02615340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Study: NCT00994643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given SC